Fisher Asset Management LLC decreased its position in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 3.0% during the third quarter, Holdings Channel reports. The fund owned 453,870 shares of the biopharmaceutical company’s stock after selling 13,900 shares during the period. Fisher Asset Management LLC’s holdings in Emergent Biosolutions were worth $14,311,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the stock. PineBridge Investments L.P. raised its stake in shares of Emergent Biosolutions by 5.4% in the second quarter. PineBridge Investments L.P. now owns 3,964 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 202 shares during the last quarter. Teacher Retirement System of Texas raised its stake in shares of Emergent Biosolutions by 22.5% in the second quarter. Teacher Retirement System of Texas now owns 4,707 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 866 shares during the last quarter. Howe & Rusling Inc. raised its stake in shares of Emergent Biosolutions by 3.0% in the second quarter. Howe & Rusling Inc. now owns 4,875 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 140 shares during the last quarter. Mason Street Advisors LLC bought a new stake in shares of Emergent Biosolutions during the second quarter worth $172,000. Finally, Springbok Capital Management LLC bought a new stake in shares of Emergent Biosolutions during the first quarter worth $192,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.
Emergent Biosolutions Inc. (NYSE:EBS) traded up 2.03% during midday trading on Friday, reaching $30.14. 233,768 shares of the company traded hands. The company has a 50 day moving average price of $28.81 and a 200-day moving average price of $31.80. Emergent Biosolutions Inc. has a one year low of $24.47 and a one year high of $44.38. The stock has a market capitalization of $1.22 billion, a P/E ratio of 28.54 and a beta of 1.03.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Monday, November 7th. The biopharmaceutical company reported $0.58 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.32. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. The business had revenue of $142.91 million for the quarter, compared to the consensus estimate of $112.30 million. During the same quarter in the prior year, the firm posted $0.93 earnings per share. The business’s revenue for the quarter was down 9.8% on a year-over-year basis. Analysts forecast that Emergent Biosolutions Inc. will post $1.02 EPS for the current fiscal year.
Several equities research analysts recently commented on the stock. Wells Fargo & Co. set a $41.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a research note on Saturday, October 1st. Chardan Capital reissued a “buy” rating and set a $47.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, November 9th. Cowen and Company reissued a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a research note on Sunday, August 7th. Zacks Investment Research raised shares of Emergent Biosolutions from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 25th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a research note on Friday, August 5th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $40.17.
About Emergent Biosolutions
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).